ESTRADIOL CONTAINING TRANSDERMAL DRUG DELIVERY SYSTEMS AND COMPOSITIONS
Transdermal drug delivery systems and compositions containing estradiol. The systems and compositions can include levulinic acid in an amount to enhance transdermal permeation of estradiol and a pharmaceutically acceptable carrier. The systems and compositions can optionally include a solubilizing agent and additional permeation enhancers. Pharmaceutically acceptable carriers can include adhesives, particularly acrylate copolymers, gels, creams, ointments, solutions, suspensions, and pastes.
1 . A transdermal drug delivery system comprising:
a composition comprising:
(a) an active agent comprising an effective amount of estradiol or a salt or a solvate or hydrate thereof; and
(b) levulinic acid in an amount suitable to enhance the transdermal permeation of estradiol, and
(c) a pharmaceutically acceptable carrier.
2 . A transdermal drug delivery system according to claim 1 wherein the carrier is an adhesive matrix.
3 . A transdermal drug delivery system according to claim 2 wherein the adhesive matrix comprises an acrylate copolymer.
4 . A transdermal drug delivery system according to claim 2 and further comprising a backing film.
5 . A transdermal drug delivery system according to claim 4 having a surface area of about 2 cm 2 to about 10 cm 2 .
6 . A transdermal drug delivery system according to claim 2 wherein the adhesive matrix is a reservoir layer and further comprising a skin-contacting adhesive layer that is distinct from the reservoir layer.
7 . A transdermal drug delivery system according to claim 6 wherein the skin-contacting adhesive layer comprises a silicone adhesive.
8 . A transdermal drug delivery system according to claim 1 , wherein the carrier is a semi-solid dosage form.
9 . A transdermal drug delivery system according to claim 8 wherein the carrier is selected from the group consisting of gel, cream, ointment, solution, suspension, and paste.
10 . A transdermal drug delivery system according to claim 1 and further comprising a solubilizing agent.
11 . A transdermal drug delivery system according to claim 10 wherein the solubilizing agent is selected from the group consisting of butylene glycol, diethylene glycol methyl ether, dipropylene glycol, propylene glycol, and mixtures thereof.
12 . A transdermal drug delivery system according to claim 10 wherein the solubilizing agent is dipropylene glycol.
13 . A transdermal drug delivery system according to claim 10 wherein the amount of solubilizing agent is between about 2 and about 6 percent by weight of the composition.
14 . A transdermal drug delivery system according to claim 1 wherein the estradiol is homogeneously dispersed within the composition.
15 . A transdermal drug delivery system according to claim 1 and further comprising one or more additional permeation enhancers selected from the group consisting of lauryl lactate, oleic acid, and mixtures thereof.
16 . A transdermal drug delivery system according to claim 15 wherein the amount of additional permeation enhancer is between about 4 and about 8 percent by weight of the composition.
17 . A transdermal drug delivery system according to claim 1 wherein the amount of estradiol is between about 2 and about 5 percent by weight of the composition.
18 . A transdermal drug delivery system according to claim 1 wherein the active agent is estradiol hemihydrate.
19 . A transdermal drug delivery system according to claim 1 wherein the amount of levulinic acid is between 5 and 25 percent by weight of the composition.
20 . A transdermal drug delivery composition comprising:
(a) an active agent comprising an effective amount of estradiol or a salt or a solvate or hydrate thereof; and
(b) levulinic acid in an amount suitable to enhance the transdermal permeation of estradiol, and
(c) a pharmaceutically acceptable carrier.
21 . A transdermal drug delivery system according to claim 2 wherein the adhesive matrix comprises an acrylate copolymer or a blend of an acrylate copolymer and a silicone polymer.